Participated · Equity · Jul 2026

410 Medical develops advanced resuscitation technologies centered on its lead product, the LifeFlow infuser, which received FDA clearance in 2016. LifeFlow is used by more than 500 hospitals and EMS agencies and has been used to treat nearly 80,000 patients experiencing conditions like sepsis and hemorrhagic shock. The company was founded in 2013 and is based in North Carolina. In July 2026 410 Medical raised $12 million in growth financing led by Orlando Health Ventures to scale commercial operations and accelerate LifeFlow adoption. The company is also investing in a next-generation LifeFlow device planned for launch in 2027. The financing was supported by a syndicate of hospital and healthcare investors, reflecting continued commercial momentum.

Participated · Series B · Aug 2025

Reprieve Cardiovascular is a clinical-stage medical device company headquartered in Milford, Massachusetts, developing the Reprieve system to personalize decongestion management for patients with acute decompensated heart failure (ADHF). The Reprieve system combines real-time physiological monitoring with automated recommendations and precise diuretic dosing while replenishing saline to support kidney function, aiming to safely, quickly, and thoroughly remove excess fluid. The company completed a randomized FASTR pilot study that met primary efficacy and safety endpoints and has initiated the larger FASTR II pivotal trial, enrolling its first patient. FASTR II plans to enroll up to 400 patients across the United States and Europe and will support a future premarket approval submission in the United States. Proceeds from the oversubscribed $61 million Series B, which combined equity investment with a debt facility, will support rapid execution of the FASTR II trial and key commercial readiness activities. Reprieve says it seeks to improve outcomes and reduce readmissions for the more than 25 million people globally who suffer from heart failure. Reprieve Cardiovascular is a development-stage, privately held medical device company developing the Reprieve System, an intelligent automated diuretic and fluid-management platform to personalize decongestion for acute decompensated heart failure patients. The system monitors physiological parameters such as urine output to deliver personalized diuretic dosing and fluid replacement, aiming to safely and quickly remove excess fluid, improve outcomes, and reduce readmissions. The company emerged from stealth after announcing a $42 million Series A to advance clinical and development programs. Proceeds will support the ongoing FASTR pilot trial (initiated in 2022) and an upcoming pivotal trial; the FASTR trial is enrolling patients in the United States and Europe. Leadership has grown with domain experts across product development, regulatory, clinical, and commercial strategy. Reprieve is headquartered in Milford, Massachusetts.

Participated · Series B · May 2025

Carta Healthcare provides an AI-powered platform that automates clinical data abstraction and analytics, combining machine learning with deep clinical expertise to extract and structure both structured and unstructured clinical data. Its technology generates actionable insights for health systems and life sciences organizations, streamlining data abstraction processes and reducing labor costs. The company plans to expand its customer footprint—particularly in the life sciences market—and to scale product deployment and operations following its late-2024 acquisition of Realyze Intelligence from UPMC Enterprises. The Realyze Intelligence acquisition added capabilities for rapidly analyzing data and identifying patients who match clinical trials and research studies. Founded in 2017 and headquartered in San Francisco, Carta reports consistent year-over-year growth and says the new capital will support hiring, infrastructure, and expanded market demand. The company’s CFO described Carta as financially healthy and positioned to strengthen its balance sheet and capture market opportunity. Carta Healthcare delivers collection, analysis, and insights into clinical data by providing registry data abstraction, reporting, and analytics to leading health systems. The company combines state-of-the-art technology with a team of experienced clinicians to produce high-quality registry data and associated analytics. By transforming the abstraction process and implementing powerful analytic capabilities, Carta informs data-driven decisions that can improve patient outcomes, reduce data-processing costs, and enable clinicians to spend more time on patient care. The company reports markedly faster data collection, superior data quality, and considerable cost savings for healthcare providers. Carta intends to use the recent funding to scale operations and accelerate product development to make more products accessible to more health systems. The business is focused on enhancing healthcare data processes and analytics to support better patient outcomes and research capabilities. Carta Healthcare provides AI-driven clinical data abstraction technology and services that use natural language processing and machine learning to reduce manual labor in curating trustworthy, actionable datasets. Its platform collects, analyzes, and layers analytic capabilities on clinical data to fuel data-driven healthcare decisions and improve patient care. The company supports the healthcare data registry market by transforming previously manual abstraction processes into automated workflows. Carta plans to use new funding to expand its clinical and technical teams and build new partnerships to make healthcare data more actionable. The company emphasizes making data-driven improvements to care delivery and bringing its solutions to new partners. Carta was founded in 2017 and is headquartered in San Francisco; it announced a recent Series A to accelerate growth.

Participated · Series B · Nov 2023

Arrivo BioVentures is advancing a pipeline of small-molecule therapeutics, including SP-624 for major depressive disorder and RABI-767 for predicted severe acute pancreatitis. SP-624 selectively activates the SIRT6 enzyme, an epigenetic mechanism, and Phase 2 data showed early, robust symptom alleviation in female subjects. RABI-767 is a pancreatic lipase inhibitor that in animal models prevents the cascade of fat necrosis and in Phase I was safe and well tolerated in healthy volunteers. Arrivo plans to use new capital to complete a Phase 2b/3 trial of SP-624, finish a Phase 2 proof-of-concept study for RABI-767, explore additional indications for SP-624, and advance activities necessary to file an NDA with the FDA for MDD. The company is led by CEO Steve Butts and notes a leadership team that has built and sold four companies over the past 15 years, with two products currently commercially available. Arrivo is based in Morrisville, N.C., and has raised $100M in total since inception.

Participated · Series B · Nov 2023

Arrivo BioVentures is a Morrisville, NC-based biopharmaceutical company focused on developing biologics and small molecules. Its operating model searches for potential products that offer improvements in patient care across multiple therapeutic areas. Lead programs include SP-624, a small molecule that selectively activates the SIRT6 enzyme being developed as a first-in-class treatment for major depressive disorder, and RABI-767, a small molecule pancreatic lipase inhibitor for preventing progression to severe acute pancreatitis. SP-624 targets a novel epigenetic mechanism known to modulate gene expression, metabolism and DNA repair. The company raised $45M in a Series B that brought total funding to $100M and intends to use proceeds to advance SP-624 through completion of a Phase 2b/3 trial and to complete a Phase 2 proof-of-concept study of RABI-767. The company is led by CEO Steve Butts. Arrivo BioVentures is a privately held drug development company based in Morrisville, N.C., on the edge of Research Triangle Park. The firm focuses on identifying and advancing biologics and small molecules, sourcing candidates in or ready for early human clinical trials. Management plans to develop four to six new drug candidates over the next several years and to in-license and initiate projects for clinical proof-of-concept and the subsequent valuation inflection point. The company closed a preferred financing with $49 million in committed capital to fund those development projects. Committed capital will be accessed over the next five years as projects are identified and initiated. The founding team includes Steve Butts, Bill Wofford, Dr. Michael Ackermann and Dr. Jed Black, who will serve as a scientific advisor; the team cites prior exits at Aerial BioPharma, Neuronex and Addrenex as evidence of its development track record.